Blueprint Medicines Corp
BPMCDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001597264
Blueprint Medicines Corp was delisted in 2025; its insiders filed their last Form 4 on Jul 21, 2025; 356 institutions reported holding it in 13F filings for Q2 2025, worth $8.66B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 356
- Q2 2025, +5 vs. previous quarter
- 13F value
- $8.65B
- Reported value at the end of Q2 2025
- Superinvestors holding
- 1
- At the end of Q2 2025
Superinvestors holding BPMC, Q2 2025
1 superinvestor reports holding Blueprint Medicines Corp on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.5%
Blueprint Medicines Corp's share of the portfolio
- Shares
- 250,000
- Value
- $32.0M
Latest insider trades
Open-market purchases and sales by Blueprint Medicines Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Rossi ChristinaCHIEF OPERATING OFFICER | SSale | −1.17K | $128.25 | −$150.3K | −1.8%63.5K after | |
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Carter Percy H.CHIEF SCIENTIFIC OFFICER | SSale | −1.05K | $128.25 | −$134.8K | −1.9%53.2K after | |
| Jun 5, 2025 (view filing) | Jun 3 | 2 days | Carter Percy H.CHIEF SCIENTIFIC OFFICER | SSale | −2.66K | $127.88 | −$340.0K | −4.7%54.2K after | 2 lots |
| May 29, 2025 (view filing) | May 27 | 2 days | Albers Jeffrey W.Director | SSale | −5.00K | $101.14 | −$505.7K | −3.3%146.6K after | 2 lots10b5-1 |
| May 21, 2025 (view filing) | May 19 | 2 days | Rossi ChristinaCHIEF OPERATING OFFICER | SSale | −2.27K | $100.51 | −$228.6K | −3.4%64.7K after | 3 lots10b5-1 |
| May 7, 2025 (view filing) | May 5 | 2 days | Rossi ChristinaCHIEF OPERATING OFFICER | SSale | −2.27K | $101.75 | −$231.4K | −3.3%67.0K after | 4 lots10b5-1 |
| May 7, 2025 (view filing) | May 5 | 2 days | Hurley ArielPRINCIPAL ACCOUNTING OFFICER | SSale | −2.75K | $103.13 | −$283.8K | −14.0%16.9K after | 3 lots10b5-1 |
| Apr 3, 2025 (view filing) | Apr 1 | 2 days | Haviland KateCHIEF EXECUTIVE OFFICER | SSale | −2.50K | $86.65 | −$216.5K | −1.5%165.9K after | 4 lots10b5-1 |
| Mar 26, 2025 (view filing) | Mar 24 | 2 days | Rossi ChristinaCHIEF OPERATING OFFICER | SSale | −2.27K | $95.02 | −$216.1K | −3.2%69.3K after | 10b5-1 |
| Mar 17, 2025 (view filing) | Mar 5 | 12 daysLate | Albers Jeffrey W.Director | SSale | −5.77K | $88.80 | −$512.0K | −3.8%146.6K after |
Top 10 13F holders, Q2 2025
The largest institutional positions in Blueprint Medicines Corp at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 6,416,603 | $822.5M | 0.01% | −223,920−3.4% | Reduced |
| BlackRock, Inc. | 6,118,428 | $784.3M | 0.02% | −592,280−8.8% | Reduced |
| Pentwater Capital Management LP | 3,900,000 | $499.9M | 6.38% | +3,900,000 | New |
| HBK Investments L P | 3,200,924 | $410.3M | 7.29% | +3,200,924 | New |
| State Street Corp | 2,230,980 | $286.0M | 0.01% | −453,137−16.9% | Reduced |
| UBS Group AG | 2,167,028 | $277.8M | 0.06% | +1,953,223+913.6% | Added |
| FIL Ltd | 1,759,500 | $225.5M | 0.19% | +1,759,500 | New |
| UBS Oconnor LLC | 1,713,587 | $219.6M | 6.00% | +1,698,722+11,427.7% | Added |
| Barclays PLC | 1,556,918 | $199.6M | 0.08% | +1,427,323+1,101.4% | Added |
| Geode Capital Management, LLC | 1,541,013 | $197.6M | 0.01% | +18,366+1.2% | Added |